X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition leverages Johnson to focus on the clinical development of ARX517, which is a PSMA inhibitor ADC. Currently it is evaluated in the clinical trial studies for the treatment of metastatic castration-resistant prostate cancer.
Lead Product(s): ARX517
Therapeutic Area: Oncology Product Name: ARX517
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $2,000.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 07, 2024
Details:
The acquisition will expand Johnson's ADC portfolio by including ARX517 targeting PSMA for mCRPC, ARX788 targeting human epidermal growth factor receptor 2 for metastatic HER2+ breast cancer, and ARX305 targeting CD-70 for renal cell carcinoma.
Lead Product(s): ARX517,Enzalutamide
Therapeutic Area: Oncology Product Name: ARX517
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $1,900.0 million Upfront Cash: $1,900.0 million
Deal Type: Acquisition January 08, 2024
Details:
ARX517 is an investigational antibody-drug conjugate composed of a humanized anti-PSMA mAb linked to AS269, an Ambrx proprietary potent microtubule inhibitor. It is being evaluated for the treatment of metastatic castration-resistant prostate cancer.
Lead Product(s): ARX517
Therapeutic Area: Oncology Product Name: ARX517
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
ARX517 is an antibody-drug conjugate composed of a fully humanized anti-PSMA mAb linked to AS269, a potent microtubule inhibitor. It is being investigated for metastatic castration-resistant prostate cancer.
Lead Product(s): ARX517
Therapeutic Area: Oncology Product Name: ARX517
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
The Company intends to use the net proceeds to fund the research and development of its product candidates, including ARX788, a next-generation, site-specific anti-HER2 ADC, being developed for the treatment of HER2-positive metastatic breast cancer.
Lead Product(s): ARX788,Capecitabine,Lapatinib Ditosylate
Therapeutic Area: Oncology Product Name: ARX788
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2023
Details:
The financing will be used in the advancement of ARX788 and ARX517. ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) covalently conjugated to two microtubule-disrupting payloads AS269.
Lead Product(s): ARX788
Therapeutic Area: Oncology Product Name: ARX788
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cowen and Company LLC
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 13, 2023
Details:
ARX788, an anti-HER2 antibody drug conjugate currently being studied broadly in breast cancer, gastric/GEJ cancer and other solid tumor clinical trials.
Lead Product(s): ARX788,Capecitabine,Lapatinib Ditosylate
Therapeutic Area: Oncology Product Name: ARX788
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
ARX517 is an antibody-drug conjugate composed of a fully humanized anti-PSMA mAb linked to AS269, a potent microtubule inhibitor. It is being investigated for metastatic castration-resistant prostate cancer.
Lead Product(s): ARX517
Therapeutic Area: Oncology Product Name: ARX517
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
ARX788, an anti-HER2 ADC being evaluated for patients whose metastatic disease is resistant or refractory to T-DXd, T-DM1, or tucatinib-containing regimens.
Lead Product(s): ARX788
Therapeutic Area: Oncology Product Name: ARX788
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2022
Details:
ARX788 is an anti-HER2 antibody drug conjugate currently being studied in several registrational trials in breast cancer and gastric/GEJ cancer in patients with HER2+ mBC) whose disease progressed following T-DM1, T-DXd and/or tucatinib-containing regimens.
Lead Product(s): ARX788
Therapeutic Area: Oncology Product Name: ARX788
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
